Morbihan disease presents a diagnostic challenge for clinicians managing chronic, persistent facial and periorbital edema. Specifically, Morbihan disease management requires a thorough understanding of its clinical presentation to avoid delayed diagnosis and permanent tissue changes. A recent retrospective study evaluated twenty-four patients to determine the most effective therapeutic approaches for this rare condition. All patients in the study exhibited bilateral eyelid involvement, while many also demonstrated extrafacial symptoms. Consequently, clinicians must recognize the characteristic firm, non-pitting edema that distinguishes this condition from common angioedema. Furthermore, histopathological examination remains a valuable tool for confirming the diagnosis, often revealing dilated lymphatic vessels.

Optimizing Morbihan Disease Management Strategies

The study categorized treatments into observation, oral steroids, intralesional injections, and combination therapies. Notably, the high-dose intralesional steroid injection group achieved a one hundred percent complete response rate. In contrast, patients receiving combination treatments showed a seventy-five percent response rate, indicating variable outcomes across different modalities. Although oral steroids provided initial relief, the recurrence rate of twelve point five percent suggests a need for long-term monitoring. Moreover, surgical options like blepharoplasty or debulking proved beneficial for patients with significant hypertrophic changes. Therefore, early intervention using potent local therapies may significantly improve the clinical trajectory for affected individuals.

Frequently Asked Questions

What are the hallmarks of Morbihan disease?

The condition is primarily characterized by chronic, firm, non-pitting edema and erythema affecting the eyelids and the upper face.

Which treatment offers the highest success rate for eyelid involvement?

According to recent study data, high-dose intralesional triamcinolone injections (20 mg/mL) provide superior complete response rates compared to oral therapies.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Choi YA et al. Clinical characteristics and treatment of Morbihan disease of the eyelids: A single-center retrospective study. Indian J Ophthalmol. 2026 Mar 12. doi: 10.4103/IJO.IJO_1493_25. PMID: 41817577.

van der Linden MMD, et al. Diagnosis and Treatment of Morbihan's Disease: A Practical Approach based on Review of the Literature. J Clin Aesthet Dermatol. 2023;16(10):22-30.

Salas-Alanís JC, et al. Morbihan disease. AME Med J. 2024;9:24.